- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Key Takeaways for Patient-Centered Management of Atopic Dermatitis
Author(s):
The panelist discusses how systemic atopic dermatitis therapies now emphasize targeted biologics and Janus kinase inhibitors, requiring personalized approaches, comprehensive monitoring, and holistic patient management.
Video Player is loading.
Video content above is provided by the following:
- Based on our discussion, what key insights or new perspectives could you share regarding treatment considerations for systemic therapies for atopic dermatitis?
- What take-home messages or practice pearls do you have for clinicians treating patients with atopic dermatitis?
Related Videos
Utility of Molecular Testing in Skin Cancer Risk Assessment
Limitations and Challenges in Skin Cancer Staging Systems
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
Mechanism of Action Differences Among IL-17 Inhibitors
The Role of IL-17 in Psoriasis Pathogenesis
Navigating the Boxed Warning for the JAK Inhibitor Class
Personalized Photoprotection Based on Patient Factors
Impact of Oxidative Stress on Skin Health and the Utility of Antioxidants
Laboratory Monitoring for JAK Inhibitors and Key Takeaways
Options for Eyebrow and Eyelash Regrowth in a 32-Year-Old Female With Alopecia Areata
Related Content
